% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

naked_finger 6 posts  |  Last Activity: Nov 12, 2015 10:27 AM Member since: Dec 9, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    56 million for phase 3

    by naked_finger Nov 12, 2015 10:27 AM
    naked_finger naked_finger Nov 12, 2015 10:27 AM Flag

    use your head, not fear.

  • naked_finger by naked_finger Nov 12, 2015 10:27 AM Flag

    this company worth 500 million in 1 year.

    Sentiment: Strong Buy

  • Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in benign prostatic hyperplasia (BPH).

    buy3Shares of Sophiris closed at $2.90 on Tuesday after jumping $2.04 on the news.

    Analyst Doug Loe writes that not only was the study a positive data point, “but particularly so when considering the multiple Phase 3 failures experienced by Sophiris’ BPH drug development peers in recent years, making the achievement of generating a positive Phase 3 efficacy signal in this difficult-to-treat medical market even more compelling.”

    The key takeaway is that “we have heightened confidence in PRX-302’s approvability in the difficult-to-treat BPH market,” he added.

    Mr. Loe also said the long-term efficacy in the PLUS-1 study from only a single intra-prostatic injection at enrollment is hugely positive for PRX-302’s medical and commercial prospects.

  • naked_finger by naked_finger Nov 11, 2015 9:42 PM Flag

    Mutual funds will be adding ...
    Also they are phase 2 prostate cancer ...
    we will see 4.00 tomorrow

    Sentiment: Strong Buy

  • naked_finger by naked_finger Nov 11, 2015 9:01 PM Flag

    Street Watchdog Research initiated coverage on Sophiris Bio (NASDAQ: SPHS) with a Buy rating and $7.50 price target. Link

    From the report: "Our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial.

    Given the substantial size of the benign prostatic hyperplasia (BPH or enlarged prostate) market, we estimate peak sales over $700 million. We believe the company will achieve a favorable outcome in its 2nd Phase III trial, which we expect to have a reduced trial completion time. As such, we are buyers of Sophiris."

    The firm said it is long the stock.

  • naked_finger by naked_finger Oct 6, 2015 10:37 AM Flag

    It needs lots of cash to get something out. All the drugs are preclinical or phase 1. With interest rate raising and need for cash sometime next year we are not going to see sunrise for some time. Buy GILD much safer.

55.52+0.75(+1.37%)1:39 PMEST